Associated Papers
Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.
Umeda M et al.
Blood, 2025
40700635 (PubMed )
Supplement: BLOOD_BLD-2025-028993-mmc2.xlsx › Supplementary_Table_6
Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.
Umeda M et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
39974131 (PubMed )
Supplement: media-2.xlsx › Supplementary_Table_6
Aging and comprehensive molecular profiling in acute myeloid leukemia.
Li JF et al.
Proceedings of the National Academy of Sciences of the United States of America, 2024
38422020 (PubMed )
Supplement: pnas.2319366121.sd02.xlsx › Sheet_1
Targeted next generation sequencing can serve as an alternative to conventional tests in myeloid neoplasms.
Kim B et al.
Plos One, 2019
30840646 (PubMed )
Supplement: pone.0212228.s004.pdf
CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay.
Ng CWS et al.
Journal of Clinical Pathology, 2018
CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.
Mannelli F et al.
Haematologica, 2017
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.
Renneville A et al.
Oncotarget, 2014
24659740 (PubMed )
Supplement: oncotarget-05-916-s001.pdf
Select a paper to view details